INFORMATIONAL WEBSITE ONLYNo products are offered for sale. No medical services are provided. Retatrutide is investigational and not FDA-approved.
Y / 001 — INVESTIGATIONAL

RETA

Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist being investigated by Eli Lilly. It is not FDA-approved and is not legally available as a medicine outside authorized clinical trials.

3RECEPTORS
338PHASE 2 PARTICIPANTS
48WEEKS STUDIED
24.2%PUBLISHED MEAN CHANGE AT 12 MG*
PHASE 3INVESTIGATIONAL STATUS
*A published finding from the highest-dose group in a controlled clinical trial of Eli Lilly investigational material. It is not evidence about a Y Peptides-branded vial, an advertisement, a recommended dose, or a promise of outcome.
Human trial

WHAT THE PHASE 2
TRIAL FOUND

In the 48-week randomized trial, mean weight change was dose-dependent: −8.7% at 1 mg, −17.1% in combined 4 mg groups, −22.8% in combined 8 mg groups, and −24.2% at 12 mg, versus −2.1% with placebo.

The study enrolled adults with obesity or overweight plus a weight-related condition. These findings apply to the trial population and investigational material used under clinical controls—not unverified retail products.

Read the NEJM paper ↗
MECHANISM THREE SIGNALS, ONE MOLECULE
GIP

Nutrient response

Engages glucose-dependent nutrient signaling pathways involved in insulin response and energy balance.

GLP-1

Satiety signaling

Engages pathways associated with appetite, gastric emptying, and glucose-dependent insulin secretion.

GCG

Energy metabolism

Engages glucagon-receptor pathways studied for effects on hepatic metabolism and energy expenditure.

PUBLISHED SAFETY
FINDINGS

This section summarizes the published clinical trial. It is not a testimonial, treatment recommendation, or information about any product offered by Y Peptides.

Reported observations

  • Gastrointestinal events were most common.
  • Events were dose-related and mostly mild to moderate.
  • Lower starting doses partly reduced GI effects.
  • Heart rate increased dose-dependently, peaked at week 24, then declined.
  • Altered or enhanced skin sensation was reported as mild to moderate.

WHAT WE STILL
DON’T KNOW.

Long-term safety and effectiveness await full phase 3 review and regulatory evaluation.

Retatrutide has not been approved by any regulatory agency and is not offered for sale on this website.

Nothing on this page provides medical advice, dosing guidance, or an invitation to obtain retatrutide.